Patient treatment summary
| Patient | Histology & Tumor Profile | NET | Tx Duration (months) | Tumor Response | Surgical Findings |
|---|---|---|---|---|---|
| A72 yStage III | Grade 1 Ductal CarcinomaER 95%, PR 90%, Ki67 16%-3% | Anastazole | 10 | 75% reduction | Partial mastectomy: residual cancer |
| B61 yStage II | Grade 1 Ductal CarcinomaER 95%, PR 95%, Ki67 5% | Anastazole | 4 | 75% reduction | Mastectomy: residual cancer 2.0 cm, neg. nodes Stage II |
| C61 yStage III | Grade 1 Lobular CarcinomaER 95%, PR 0%, Ki67 5% | Anastazole | 4 | 7% reduction | Mastectomy: residual cancer 24 cm, 24 positive nodes Stage III |
| D46 yStage III | Grade 2 Ductal CarcinomaER 95%, PR 95%,Ki67 50%-60% | Leuprolide and Tamoxifen | 2 | 4% growth | Mastectomy: residual cancer 2 cm, 4 positive nodes Stage II |
| E77 yStage II | Grade 2Lobular CarcinomaER 95%, PR 10%, Ki67 8% | Anastazole | 4 | 32% reduction | Pending partial mastectomy |